LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Elenco Azioni・United Therapeutics Corp

United Therapeutics Corp

Chiusa

SettoreSettore sanitario

569.57 1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

563.94

Massimo

580.21

Metriche Chiave
By Trading Economics
Entrata	26M 364M
Vendite	-9.3M 790M
P/E Media del settore	20.877 49.8
Margine di Profitto	46.102
Dipendenti	1,400
EBITDA	61M 524M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+14.7% upside

Dividendi
By Dow Jones
Utili prossimi	29 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	3.2B 25B
Apertura precedente	568.57
Chiusura precedente	569.57

Notizie sul Sentiment di mercato

By Acuity

92%

3 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

292.345 / 309.245 Supporto e resistenza

United Therapeutics Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mag 2026, 23:47 UTC

Discorsi di Mercato

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mag 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mag 2026, 23:38 UTC

Discorsi di Mercato

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mag 2026, 23:14 UTC

Discorsi di Mercato

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mag 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mag 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mag 2026, 10:21 UTC

Utili

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mag 2026, 06:05 UTC

Utili

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

United Therapeutics Corp Previsione

Obiettivo di Prezzo

By TipRanks

14.7% in crescita

Previsioni per 12 mesi

Media 648 USD 14.7%

Alto 738 USD

Basso 516 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per United Therapeutics Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a United Therapeutics Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

292.345 / 309.245Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

3 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.